RAPT Therapeutics
RAPT
RAPT was delisted on the 2nd of March, 2026.
98 hedge funds and large institutions have $721M invested in RAPT Therapeutics in 2022 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 38 increasing their positions, 20 reducing their positions, and 8 closing their positions.
175% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 8
90% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 20
33% more capital invested
Capital invested by funds: $543M → $721M (+$178M)
17% more funds holding
Funds holding: 84 → 98 (+14)
0.1% more ownership
Funds ownership: 12.53% → 12.63% (+0.1%)
0% more funds holding in top 10
Funds holding in top 10: 9 → 9 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$18.5M |
| 2 |
O
OrbiMed
New York
|
+$9.1M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$8.26M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$7.45M |
| 5 |
Nuveen
Charlotte,
North Carolina
|
+$4.37M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$29.7M |
| 2 |
KXA
KPCB XV Associates
Menlo Park,
California
|
-$15.3M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$12.3M |
| 4 |
KCM
Kingdon Capital Management
New York
|
-$8.22M |
| 5 |
ROTUOC
Regents of the University of California
Oakland,
California
|
-$7.69M |
RAPT Hedge Fund Activity: Q3 2022 in Review
98 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in RAPT Therapeutics (RAPT) for Q3 2022, worth a combined $721M — up 33% from $543M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new RAPT positions and 8 closed out — a net gain of 14 holders — while 38 added to existing stakes and 20 trimmed.
The largest buyer was State Street, adding an estimated $18.5M. The largest seller was T. Rowe Price Associates, cutting an estimated $29.7M.
- 98 institutional investors held RAPT Therapeutics (RAPT) as of Q3 2022, up from 84 in Q2 2022.
- Funds reported $721M of RAPT Therapeutics stock for Q3 2022, up 33% quarter-over-quarter.
- 22 funds opened new RAPT Therapeutics positions in Q3 2022 and 8 closed out, a net change of +14 holders.
- The largest RAPT Therapeutics buyer in Q3 2022 was State Street, an estimated $18.5M added.
- The largest RAPT Therapeutics seller in Q3 2022 was T. Rowe Price Associates, an estimated $29.7M sold.
Based on aggregated 13F filings for Q3 2022.